Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees
Saved in:
| Published in | The Journal of infection Vol. 84; no. 4; pp. 579 - 613 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.04.2022
The British Infection Association. Published by Elsevier Ltd |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Author | Lu, Hongzhou Liu, Yingxia Tang, Yimin YangYang Ye, Guoguo Gong, Xiaohua Li, Jianhuan Wei, Lanlan Yang, Liuqing Li, Jie Lin, Yuanlong Zhang, Jiaqi Jiang, Yujing Wang, Fuxiang |
|---|---|
| Author_xml | – sequence: 1 surname: YangYang fullname: YangYang – sequence: 2 givenname: Xiaohua surname: Gong fullname: Gong, Xiaohua – sequence: 3 givenname: Liuqing surname: Yang fullname: Yang, Liuqing – sequence: 4 givenname: Jie surname: Li fullname: Li, Jie – sequence: 5 givenname: Jiaqi surname: Zhang fullname: Zhang, Jiaqi – sequence: 6 givenname: Lanlan surname: Wei fullname: Wei, Lanlan – sequence: 7 givenname: Guoguo surname: Ye fullname: Ye, Guoguo – sequence: 8 givenname: Yimin surname: Tang fullname: Tang, Yimin – sequence: 9 givenname: Yujing surname: Jiang fullname: Jiang, Yujing – sequence: 10 givenname: Jianhuan surname: Li fullname: Li, Jianhuan – sequence: 11 givenname: Yuanlong surname: Lin fullname: Lin, Yuanlong – sequence: 12 givenname: Fuxiang surname: Wang fullname: Wang, Fuxiang – sequence: 13 givenname: Hongzhou surname: Lu fullname: Lu, Hongzhou – sequence: 14 givenname: Yingxia orcidid: 0000-0001-6335-3346 surname: Liu fullname: Liu, Yingxia email: yingxialiu@hotmail.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35016900$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUktvEzEQtlARTQt_gAPykUuCH_tECAlVvKRKlRCcrVnvbDLpxltsb1D4P_2f9Sahgh7KybLne4znmzN24gaHjL2UYiGFLN6sF2ty3UIJpRZCLoTInrCZzLWaqzJTJ2yWQHqeZbk-ZWchrIUQta6LZ-xU56lUCzFjt99wOfbgObiWN8MQInq-BWvJQaTB8V8UVzxdbKQtRGyPRQwc3QqcRR5XyB2O0UNPv8kt-R5LccdhCeRC5Fcbsj5pbcETuJh89pp7ZuMRruPKD-NyeuvQTrZh38_RCsNz9rSDPuCL43nOfnz6-P3iy_zy6vPXiw-Xc5uLIs4hLxoourpuKotWVVqVbYGqaIXEaUplXVRNpTuLbaXb3ArdYidRQl5C1YhOn7P3B92bsdlga9FNvzI3njbgd2YAMv9WHK3Mctiaqsx0Wesk8Poo4IefI4ZoNhQs9j04HMZgVCFrJeosqxL01d9e9yZ_skkAdQCk2YXgsbuHSGGmBTBrMy2Amb5mhDRpARKpekCyFPdJpn6pf5z67kDFNOEtoTfBEqaEW_IpFdMO9Dj97QO67cmRhf4ad_8j3wFF5uWq |
| CitedBy_id | crossref_primary_10_1038_s41421_022_00443_w crossref_primary_10_3389_fimmu_2022_947602 crossref_primary_10_1001_jamanetworkopen_2022_10780 crossref_primary_10_1038_s41392_022_01023_w crossref_primary_10_1111_crj_13694 crossref_primary_10_1080_22221751_2022_2151381 crossref_primary_10_1016_j_heliyon_2023_e23344 crossref_primary_10_1016_j_jinf_2022_05_001 crossref_primary_10_3389_fimmu_2022_897879 crossref_primary_10_1016_j_msard_2022_103933 crossref_primary_10_1016_j_jinf_2024_106208 crossref_primary_10_1016_j_jinf_2022_10_021 crossref_primary_10_1002_jmv_28049 crossref_primary_10_1186_s12889_024_17958_4 crossref_primary_10_3389_fmed_2024_1401439 crossref_primary_10_1093_infdis_jiac092 crossref_primary_10_1126_scitranslmed_abm7621 crossref_primary_10_5582_bst_2022_01062 crossref_primary_10_1016_S2666_5247_23_00139_8 crossref_primary_10_12677_AMB_2022_112006 |
| Cites_doi | 10.1038/s41586-021-03696-9 10.1038/s41576-021-00408-x 10.1093/cid/ciab1041 10.1016/j.immuni.2021.07.008 10.1056/NEJMc2114706 10.1016/j.cell.2021.01.050 10.1016/j.jinf.2021.07.019 |
| ContentType | Journal Article |
| Copyright | 2022 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. 2022 |
| Copyright_xml | – notice: 2022 – notice: 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.jinf.2022.01.004 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1532-2742 |
| EndPage | 613 |
| ExternalDocumentID | PMC8743793 35016900 10_1016_j_jinf_2022_01_004 S0163445322000056 |
| Genre | Letter Research Support, Non-U.S. Gov't |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABGAM ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AI. AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMK HMO HVGLF HZ~ IHE J1W J5H KOM L7B LUGTX M27 M41 MO0 N9A O-L O9- OAUVE OD- OO. OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K UHS VH1 WUQ YHZ Z5R ZGI ~G- AACTN AFCTW RIG SSI AAYXX AGRNS CITATION AFKWA AJOXV AMFUW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c506t-a56ba6f99b8cec28327d6e26d01e20227968b83fced83d5c03def1e1a57a8b0f3 |
| IEDL.DBID | .~1 |
| ISSN | 0163-4453 1532-2742 |
| IngestDate | Thu Aug 21 13:23:23 EDT 2025 Tue Aug 05 10:05:45 EDT 2025 Wed Feb 19 02:25:51 EST 2025 Thu Apr 24 22:55:36 EDT 2025 Tue Jul 01 01:01:13 EDT 2025 Sun Apr 06 06:53:18 EDT 2025 Tue Aug 26 16:45:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c506t-a56ba6f99b8cec28327d6e26d01e20227968b83fced83d5c03def1e1a57a8b0f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 23 These authors contributed equally to this study. |
| ORCID | 0000-0001-6335-3346 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8743793 |
| PMID | 35016900 |
| PQID | 2619209448 |
| PQPubID | 23479 |
| PageCount | 35 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8743793 proquest_miscellaneous_2619209448 pubmed_primary_35016900 crossref_primary_10_1016_j_jinf_2022_01_004 crossref_citationtrail_10_1016_j_jinf_2022_01_004 elsevier_sciencedirect_doi_10_1016_j_jinf_2022_01_004 elsevier_clinicalkey_doi_10_1016_j_jinf_2022_01_004 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-01 |
| PublicationDateYYYYMMDD | 2022-04-01 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | The Journal of infection |
| PublicationTitleAlternate | J Infect |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd The British Infection Association. Published by Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd – name: The British Infection Association. Published by Elsevier Ltd |
| References | Gidari (bib0001) 2021; 83 Uriu (bib0007) 2021; 385 Muecksch (bib0008) 2021; 54 Wang (bib0010) 2021; 595 Yang (bib0004) 2021; 6 Sokal (bib0009) 2021; 184 Luna-Muschi (bib0002) 2021 Cao (bib0006) 2021; 585 Tao (bib0003) 2021; 22 Lu (bib0005) 2021 Gidari (10.1016/j.jinf.2022.01.004_bib0001) 2021; 83 Yang (10.1016/j.jinf.2022.01.004_bib0004) 2021; 6 Wang (10.1016/j.jinf.2022.01.004_bib0010) 2021; 595 Sokal (10.1016/j.jinf.2022.01.004_bib0009) 2021; 184 Luna-Muschi (10.1016/j.jinf.2022.01.004_bib0002) 2021 Uriu (10.1016/j.jinf.2022.01.004_bib0007) 2021; 385 Cao (10.1016/j.jinf.2022.01.004_bib0006) 2021; 585 Muecksch (10.1016/j.jinf.2022.01.004_bib0008) 2021; 54 Lu (10.1016/j.jinf.2022.01.004_bib0005) 2021 Tao (10.1016/j.jinf.2022.01.004_bib0003) 2021; 22 |
| References_xml | – year: 2021 ident: bib0005 article-title: Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients publication-title: Clin Infect Dis – volume: 585 year: 2021 ident: bib0006 article-title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies publication-title: Nature – volume: 22 start-page: 757 year: 2021 end-page: 773 ident: bib0003 article-title: The biological and clinical significance of emerging SARS-CoV-2 variants publication-title: Nat Rev Genet – volume: 54 year: 2021 ident: bib0008 article-title: Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations publication-title: Immunity – volume: 6 year: 2021 ident: bib0004 article-title: Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection publication-title: Nature Mocribiol – volume: 595 start-page: 426 year: 2021 end-page: 431 ident: bib0010 article-title: Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection publication-title: Nature – volume: 83 start-page: 467 year: 2021 end-page: 472 ident: bib0001 article-title: Cross-neutralization of SARS-CoV-2 B1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected publication-title: J Infect – year: 2021 ident: bib0002 article-title: Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: a prospective cohort study of vaccinated and unvaccinated healthcare workers publication-title: J Infect – volume: 184 year: 2021 ident: bib0009 article-title: Maturation and persistence of the anti-SARS-CoV-2 memory B cell response publication-title: Cell – volume: 385 start-page: 2397 year: 2021 end-page: 2399 ident: bib0007 article-title: Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum publication-title: N Engl J Med – volume: 595 start-page: 426 year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0010 article-title: Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection publication-title: Nature doi: 10.1038/s41586-021-03696-9 – volume: 22 start-page: 757 year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0003 article-title: The biological and clinical significance of emerging SARS-CoV-2 variants publication-title: Nat Rev Genet doi: 10.1038/s41576-021-00408-x – year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0005 article-title: Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients publication-title: Clin Infect Dis doi: 10.1093/cid/ciab1041 – volume: 54 year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0008 article-title: Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations publication-title: Immunity doi: 10.1016/j.immuni.2021.07.008 – volume: 385 start-page: 2397 year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0007 article-title: Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum publication-title: N Engl J Med doi: 10.1056/NEJMc2114706 – volume: 6 year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0004 article-title: Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection publication-title: Nature Mocribiol – volume: 184 year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0009 article-title: Maturation and persistence of the anti-SARS-CoV-2 memory B cell response publication-title: Cell doi: 10.1016/j.cell.2021.01.050 – volume: 83 start-page: 467 year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0001 article-title: Cross-neutralization of SARS-CoV-2 B1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected publication-title: J Infect doi: 10.1016/j.jinf.2021.07.019 – volume: 585 year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0006 article-title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies publication-title: Nature – year: 2021 ident: 10.1016/j.jinf.2022.01.004_bib0002 article-title: Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: a prospective cohort study of vaccinated and unvaccinated healthcare workers publication-title: J Infect |
| SSID | ssj0009396 |
| Score | 2.4632168 |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 579 |
| SubjectTerms | Antibodies, Neutralizing Antibodies, Viral Humans Immunization, Secondary Letter to the Editor Vaccination Vaccines, Inactivated |
| Title | Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0163445322000056 https://dx.doi.org/10.1016/j.jinf.2022.01.004 https://www.ncbi.nlm.nih.gov/pubmed/35016900 https://www.proquest.com/docview/2619209448 https://pubmed.ncbi.nlm.nih.gov/PMC8743793 |
| Volume | 84 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9NQ0JICMH4Kh-TkXhDoUlsx8njNDEVqg1pMLE3y7GdrQO8aW154IH_hv-TO8cpFNCQeKrS3NVW73z-nX0fAM8luggVV7i-HS43qs-emaIxmRKdEo2yrYvp0fsH1eRIvDmWxxuwO-TCUFhlsv29TY_WOn0zTv_m-GI2G79DsMKFkKiRZHQlld0WQpGWv_z2M8yj4bFHFxFnRJ0SZ_oYrzOUIvqIZRlLd6ZmbX_ZnP4En7_HUP6yKe3dhlsJTbKdfsJ3YMOHLbi-n-7Lt-BmfyrH-mSju_D9MLaev2QmOIb4mqoksC_GInWUEKNjWYYPNnY98y699HPmwykpCEPAyIJfxgOSr7jvsUiLWJ6ZEzNDsMnefqYgv4CsqNxhgePE34yc6ICbj6k3EBsCwcI8zicN5ef34Gjv1fvdSZYaNWRW5tUiM7JqTdU1TVtbb6n5kXKVLyuXF76MNQqruq15hzKtuZM25853hS-MVKZu847fh81wHvxDYLx06KE5g8DQCc9lYxEfdgbtkPS-sWIExSAhbVMVc2qm8UkP4WpnmqSqaVydFxqlOoIXK56LvobHldR8ELweslPRnmrcYq7kkiuuNf39J9-zQbc0Lmy6rTHBny_nOrq26HyLegQPel1bzZ5ug6smz0eg1rRwRUBFw9ffhNlpLB5eK6pAyR_953wfww166mOXnsDm4nLpnyIsW7Tbcd1tw7Wd19PJAX1ODz9MfwDJVTz9 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9QwDLfGkAAJITa-bnxlEm-oXNs0afuIJqYDdps0NmlvUZqk7AZk0-6OBx74b_Z_YqfpbQdoSDy2sZuodpyfE8cGeCXQRZC8xPltcbpRfvZEZ7VOyqIti7o0jQ3Xo8e7cnRYfDgSRyuw1d-FobDKaPs7mx6sdXwzjH9zeDaZDD8hWOFFIVAjyegKeQNu4lNFZQze_LyM86h5KNJF1AmRx5szXZDXCYoRncQ8D7k7Y7W2v6xOf6LP34Mor6xK2_fhXoST7G034jVYcX4dbo3jgfk63O225Vh32-gBXOyH2vPnTHvLEGBTmgT2XRukDiJitC_L8MGEsmfOxkY3Zc4fk4YwRIzMu3nYIfmBCx8LtAjmmf6sJ4g22d43ivLzyIra7WfYT_hm4EQPXH-JxYFYHwnmp2E8sSs3fQiH2-8OtkZJrNSQGJHKWaKFbLRs67qpjDNU_ai00uXSppnLQ5JCWTUVb1GoFbfCpNy6NnOZFqWumrTlj2DVn3r3BBjPLbpoViMytIXjojYIEFuNhkg4V5tiAFkvIWViGnOqpvFV9fFqJ4qkqqhflWYKpTqA1wuesy6Jx7XUvBe86q-nokFVuMZcyyUWXEsK_E--zV63FM5sOq7R3p3Opyr4tuh9F9UAHne6thg9HQfLOk0HUC5p4YKAsoYvt_jJccgeXpWUgpJv_Od4X8Lt0cF4R-283_34FO5QSxfI9AxWZ-dz9xwx2qx5EebgL8BQPOg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Regular+and+booster+vaccination+with+inactivated+vaccines+enhance+the+neutralizing+activity+against+Omicron+variant+both+in+the+breakthrough+infections+and+vaccinees&rft.jtitle=The+Journal+of+infection&rft.au=YangYang&rft.au=Gong%2C+Xiaohua&rft.au=Yang%2C+Liuqing&rft.au=Li%2C+Jie&rft.date=2022-04-01&rft.pub=Elsevier+Ltd&rft.issn=0163-4453&rft.volume=84&rft.issue=4&rft.spage=579&rft.epage=613&rft_id=info:doi/10.1016%2Fj.jinf.2022.01.004&rft.externalDocID=S0163445322000056 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0163-4453&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0163-4453&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0163-4453&client=summon |